The National Association of Community Health Centers urged Congress and the Biden administration this afternoon to force drug companies to ship 340B drugs to contract pharmacies unconditionally and stop pharmacy benefit managers from siphoning off health centers’ 340B savings.
NACHC
…
Biopharmaceutical manufacturer Exelixis yesterday became the 17th drug maker to impose conditions on 340B pricing when hospitals use contract pharmacies.
The company, a specialty manufacturer with two high-priced drug products on the market, announced its policy in email notices to covered
…
Twenty-five states are backing the federal government in litigation before two federal appeals courts over drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
A bipartisan group of state attorneys general filed friend of the court briefs this
…
Drug manufacturer Merck today extended its restrictions on 340B pricing involving contract pharmacies to community health centers. The restrictions have applied only to hospital covered entities until now.
Other grantee covered entities remain exempt “at this time,” Merck said, adding
…
The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”
HRSA told BI in a March 29
…
Drug manufacturer Johnson & Johnson this afternoon announced conditions on 340B sales on 29 products—including several of its top-selling drugs—when hospitals use contract pharmacies. Grantees are exempt from the requirements, which take effect May 2.
J&J’s mid-day notice to customers
…
The National Association of Community Health Centers (NACHC) told drug manufacturer Gilead this morning its new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments are “unconscionable,” “appalling,” “wrongheaded,” and “the latest example of corporate greed from
…
UPDATE Friday, March 18, 2022, 1:30 p.m. EDT—The U.S. Health Resources and Services Administration (HRSA) told 340B Report shortly after this story was published, “To be eligible, [a] hospital’s termination must have been as a result of actions taken by
…
Gilead late yesterday imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies. It is the 15th manufacturer to place restrictions on its 340B contract pharmacy program.
The policy, which applies to hospital
…
The U.S. Senate last night passed a $1.5 trillion federal appropriations bill with language to help some hospitals forced out of the 340B program during the COVID-19 pandemic.
The House passed the bill Wednesday night. President Biden is expected
…*Sign up for news summaries and alerts from 340B Report